i
Update on recommendations for use of herpes zoster vaccine
-
August 22, 2014
-
[PDF-195.85 KB]
Details:
-
Journal Article:MMWR. Morbidity and mortality weekly report
-
Personal Author:
-
Corporate Authors:
-
Description:Herpes zoster vaccine (Zostavax [Merck & Co., Inc.]) was licensed in 2006 and recommended by the Advisory Committee on Immunization Practices (ACIP) in 2008 for prevention of herpes zoster (shingles) and its complications among adults aged ≥60 years. The Food and Drug Administration (FDA) approved the use of Zostavax in 2011 for adults aged 50 through 59 years based on a large study of safety and efficacy in this age group. ACIP initially considered the use of herpes zoster vaccine among adults aged 50 through 59 years in June 2011, but declined to recommend the vaccine in this age group, citing shortages of Zostavax and limited data on long-term protection afforded by herpes zoster vaccine. In October 2013, ACIP reviewed the epidemiology of herpes zoster and its complications, herpes zoster vaccine supply, short-term vaccine efficacy in adults aged 50 through 59 years, short- and long- term vaccine efficacy and effectiveness in adults aged ≥60 years, an updated cost-effectiveness analysis, and deliberations of the ACIP herpes zoster work group, all of which are summarized in this report. No vote was taken, and ACIP maintained its current recommendation that herpes zoster vaccine be routinely recommended for adults aged ≥60 years. Meeting minutes are available at http://www.cdc.gov/vaccines/acip/meetings/meetings-info.html.
Citation: Hales CM, Harpaz R, Ortega-Sanchez I, Bialek SR; Centers for Disease Control and Prevention (CDC). Update on recommendations for use of herpes zoster vaccine.MMWR Morb Mortal Wkly Rep. 2014 Aug 22;63(33):729-31.
PMID: 25144544
-
Content Notes:Bauman
8/28/2015
-
Subjects:
-
Series:
-
Document Type:
-
Genre:
-
Place as Subject:
-
Location:
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
